M. Kulyk & Associates’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.3M Sell
73,699
-270
-0.4% -$37.8K 1.92% 16
2025
Q4
$9.08M Buy
73,969
+1,655
+2% +$201K 1.73% 19
2025
Q3
$8.03M Sell
72,314
-1,939
-3% -$220K 1.63% 20
2025
Q2
$8.23M Buy
74,253
+1,384
+2% +$147K 1.79% 16
2025
Q1
$8.17M Sell
72,869
-15,797
-18% -$1.63M 1.87% 17
2024
Q4
$8.19M Sell
88,666
-11,801
-12% -$1.06M 1.77% 17
2024
Q3
$8.42M Sell
100,467
-3,412
-3% -$260K 1.69% 17
2024
Q2
$7.13M Buy
103,879
+14,651
+16% +$978K 1.66% 20
2024
Q1
$6.54M Buy
89,228
+5,795
+7% +$446K 1.52% 23
2023
Q4
$6.76M Sell
83,433
-919
-1% -$71.5K 1.57% 22
2023
Q3
$6.32M Buy
84,352
+1,337
+2% +$103K 1.76% 14
2023
Q2
$6.4M Sell
83,015
-5,855
-7% -$467K 1.79% 15
2023
Q1
$7.37M Buy
88,870
+1,021
+1% +$84.6K 2.23% 12
2022
Q4
$7.54M Sell
87,849
-193
-0.2% -$15.3K 2.52% 9
2022
Q3
$5.43M Buy
88,042
+1,572
+2% +$99.1K 1.89% 13
2022
Q2
$5.34M Buy
86,470
+3,275
+4% +$203K 1.66% 17
2022
Q1
$4.95M Sell
83,195
-19,076
-19% -$1.22M 1.35% 29
2021
Q4
$7.43M Buy
102,271
+5,329
+5% +$367K 1.92% 14
2021
Q3
$6.77M Buy
96,942
+4,741
+5% +$333K 2.17% 10
2021
Q2
$6.35M Buy
92,201
+9,122
+11% +$609K 2.29% 9
2021
Q1
$5.37M Buy
83,079
+28,219
+51% +$1.82M 2% 11
2020
Q4
$3.2M Buy
+54,860
New +$3.31M 1.77% 25

Other funds holding GILD

M. Kulyk & Associates's GILD Position: Q1 2026 in Review

M. Kulyk & Associates reduced its Gilead Sciences (GILD) stake by 0.37% in Q1 2026, selling an estimated $37.8K and leaving 73,699 shares worth $10.3M. The position accounts for 1.92% of the portfolio, ranked #16.

M. Kulyk & Associates first reported a position in GILD in Q4 2020 and has held it in 22 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • M. Kulyk & Associates held 73,699 shares of Gilead Sciences worth $10.3M as of Q1 2026.
  • M. Kulyk & Associates sold 270 Gilead Sciences shares in Q1 2026, an estimated $37.8K.
  • Gilead Sciences made up 1.92% of M. Kulyk & Associates's portfolio in Q1 2026, its #16 holding.
  • M. Kulyk & Associates first reported a position in Gilead Sciences in Q4 2020 and has held it in 22 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on M. Kulyk & Associates's 13F filing for Q1 2026, filed 6 May 2026.